| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Cancer Research and Treatment Search > Browse Articles > Search



Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy
Jeongshim Lee, Jee Suk Chang, Mi Ryung Roh, Minkyu Jung, Choong-Kun Lee, Byung Ho Oh, Kee Yang Chung, Woong Sub Koom, Sang Joon Shin
Cancer Res Treat. 2020;52(3):730-738.   Published online February 13, 2020    DOI: https://doi.org/10.4143/crt.2019.598
                              Supplementary      
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Res Treat. 2020;52(2):594-603.   Published online December 18, 2019    DOI: https://doi.org/10.4143/crt.2019.493
                                 Cited By 2
Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects
Chul Won Choi, Min Ho Jeong, You-Soo Park, Cheol-Hun Son, Hong-Rae Lee, Eun-Kyoung Koh
Cancer Res Treat. 2019;51(2):464-473.   Published online June 6, 2018    DOI: https://doi.org/10.4143/crt.2018.186
                              Supplementary         Cited By 6
Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report
Haa-Na Song, Min Gyu Kang, Jeong Rang Park, Jin-Yong Hwang, Jung Hun Kang, Won Seop Lee, Gyeong-Won Lee
Cancer Res Treat. 2018;50(4):1458-1461.   Published online January 22, 2018    DOI: https://doi.org/10.4143/crt.2017.529
                                 Cited By 1
Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
Minkyu Jung, Jeeyun Lee, Tae Min Kim, Dae Ho Lee, Jin Hyung Kang, Sung Young Oh, Soo Jung Lee, Sang Joon Shin
Cancer Res Treat. 2017;49(1):44-53.   Published online April 27, 2016    DOI: https://doi.org/10.4143/crt.2016.024
                                 Cited By 14
Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy
Sung Han Kim, Weon Seo Park, Sun Ho Kim, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Cancer Res Treat. 2016;48(3):1092-1101.   Published online January 28, 2016    DOI: https://doi.org/10.4143/crt.2015.316
                                 Cited By 16
Improved Efficacy of a Dendritic Cell-Based Vaccine against a Murine Model of Colon Cancer: The Helper Protein Effect
Amir-Hassan Zarnani, Monireh Torabi-Rahvar, Mahmood Bozorgmehr, Mehri Zareie, Nazanin Mojtabavi
Cancer Res Treat. 2015;47(3):518-526.   Published online November 27, 2014    DOI: https://doi.org/10.4143/crt.2013.241
                                 Cited By 7
Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer
Min-Ho Park, Deok-Hwan Yang, Mi-Hyun Kim, Jae-Hong Jang, Yoon-Young Jang, Youn-Kyung Lee, Chun-Ji Jin, Than Nhan Nguyen Pham, Truc Anh Nguyen Thi, Mi-Seon Lim, Hyun-Ju Lee, Cheol Yi Hong, Jung-Han Yoon, Je-Jung Lee
Cancer Res Treat. 2011;43(1):56-66.   Published online March 31, 2011    DOI: https://doi.org/10.4143/crt.2011.43.1.56
                                 Cited By 9
The Effect of Immunotherapy Based on Interferon - alpha in Advanced Renal Cell Carcinoma
Seung Hyun Jeon, Sung Goo Chang
J Korean Cancer Assoc. 1999;31(5):986-994.
      
Immunoregulatory Effect of Mesima (R) as an Immunotherapeutic Agent in Stage III Gastric Cancer Patients after Radical Gastrectomy
Jin Pok Kim, Keon Young Lee, Hang Jong Yu, Han Kwang Yang
J Korean Cancer Assoc. 1997;29(3):383-390.
      
Korean Cancer Association
E-Submission
EndNote Output Style
Email Alert
Impact factor
SCImago Journal & Country Rank
PubMed Central
MEDLINE/PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
COPE
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association. All rights reserved.                 Developed in M2Community